Letter from Iran: Experiences with <scp>COVID</scp>‐19

Abbasi-Oshaghi, Ebrahim; Mirzaei, Fatemeh; Khodadadi, Iraj

doi:10.1111/resp.13948

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Abbasi-Oshaghi et al, 2020 , Ciuffini et al, 2021 , Zavareh et al, 2018 , Nordfjaern et al, 2021 , Rundmo et al, 2011 , Sjöberg et al, 2004 , Wong and Ling, and Olivia Jensen. , 2020 .…”

Section: Uncited Referencesmentioning

confidence: 99%

Demand for mitigating the risk of COVID-19 infection in public transport: The role of social trust and fatalistic beliefs

Zavareh

Mehdizadeh

Nordfjærn

2022

Transportation Research Part F: Traffic Psychology and Behaviou

View full text Add to dashboard Cite

The rapid surge of COVID-19 cases worldwide drew attention to COVID-19 infection as a new source of risk in transport. The virus introduced a need for viral transmission mitigation as a major priority when selecting a mode of travel, and caused a significant drop in public transport use. The recovery of public transport use in the post-COVID period requires that the transport authorities favourably address the people’s demand for mitigation of the risk of COVID-19 transmission in public transport. The present study aims to explore the role of risk perception, worry and priority of COVID-19 risk reduction along with fatalistic beliefs and public trust in authorities in explaining public demand for risk mitigation. The present study is among the first to investigate the role of fatalistic beliefs, social trust and risk perception for public transport and public demand for risk mitigation. The link between priority of infection prevention and demand for risk mitigation has also been less explored in public transport research. An online survey was conducted among university students in Iran between 19 th April and 16 th June 2020, during the first wave of the pandemic, when the country was a major epicentre of the disease. A total of 271 out of 370 respondents whose dominant mode on university travels was public transport were included in the analysis. Results of structural equation modelling confirmed the paradox of trust, indicating that social trust is negatively associated with perceived risk of COVID-19 infection, which in turn may lead people to place less importance on COVID-19 prevention as a priority in travel mode choice, and consequently demand less risk mitigation efforts to prevent COVID-19 infection in public transport. Dissimilar to trust, however, the results revealed no relationship between fatalistic beliefs and risk perception, but a significant direct effect of fatalistic beliefs on demand for risk mitigation. To reinforce public demand for mitigating the risk of COVID-19 in public transport, the study calls on policymakers to exploit public trust resources for more effective risk communication, through disseminating the gradually accumulating evidence-based information regarding the infectivity and the virulence of COVID-19 and the scientific risk of infection. The study also underlined the potential importance of considering fatalistic beliefs when developing effective risk communication policies and practices to enhance public support for COVID-19 risk mitigation in public transport.

show abstract

“… Abbasi-Oshaghi et al, 2020 , Ciuffini et al, 2021 , Zavareh et al, 2018 , Nordfjaern et al, 2021 , Rundmo et al, 2011 , Sjöberg et al, 2004 , Wong and Ling, and Olivia Jensen. , 2020 .…”

Section: Uncited Referencesmentioning

confidence: 99%

Demand for mitigating the risk of COVID-19 infection in public transport: The role of social trust and fatalistic beliefs

Zavareh

Mehdizadeh

Nordfjærn

2022

Transportation Research Part F: Traffic Psychology and Behaviou

View full text Add to dashboard Cite

show abstract

“…The disease affected millions of people worldwide (1), leading to more than 673 million contractions and 3 million deaths worldwide as of January 1, 2023 (2). COVID-19 is a highly infectious disease that affects the lungs and immune system and emerges clinically with fever, cough, and shortness of breath (3,4). The clinical course of the SARS-CoV-2 infection varies considerably, with some patients showing a mild disease while others develop more severe conditions that may require a long time to recover or even be fatal (3,5).…”

Section: Introductionmentioning

confidence: 99%

Determination of Serum Calprotectin, Heparin-Binding Protein, and Some Inflammatory Factors in Patients with COVID-19

Mardani,

Mousavi-Nasab,

Shahali

et al. 2023

Arch Clin Infect Dis

Self Cite

View full text Add to dashboard Cite

Background: Among the serum biomarkers of infectious diseases, calprotectin and heparin-binding protein (HBP) seem to be of clinical and diagnostic value in patients with COVID-19. Objectives: This study aimed to investigate the serum levels of calprotectin, HBP, and some other inflammatory markers in COVID-19 patients. Methods: In this case-control study, serum samples of 35 outpatients with COVID-19 and 35 healthy individuals were collected, and the levels of calprotectin, HBP, C-reactive protein (CRP), ferritin (FERR), as well as platelet (PLT) and neutrophil (NEU) counts and LDH activity, were determined. Results: At first, SARS-CoV2 viral RNA was detected in the pharyngeal swab specimens of COVID-19 patients. Calprotectin, FERR, and CRP levels, LDH activity, and PLT and NEU counts were found to be significantly higher in COVID-19 patients compared with controls (P < 0.05), whereas no statistically significant difference was observed in HBP level (P > 0.05). Serum calprotectin showed a significant correlation with CRP and FERR levels, LDH activity, and NEU count (P < 0.001). Conclusions: Our findings showed that an increment in serum calprotectin level, together with increased CRP levels, might be a promising indicator of SARS-CoV2 infection.

show abstract

“…Within about two months, the 2019-nCoV spread rapidly throughout China and other parts of the world. Therefore, at present, the number of cases outside of China is very high, and infected cases have been reported in all part of the word [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

Diabetes and COVID-19: Mechanism of pneumonia, treatment strategy and vaccine

et al. 2021

Self Cite

View full text Add to dashboard Cite

As of August 5, 2021, there were about 200,000,000 global confirmed patients of COVID-19, with more than 4,250,000 deaths. The COVID-19 disease which is a tremendous public health threat, jumps unpredictably and outbreaks very quickly. The overall mortality rate of COVID-19 infection is 1%–15% but reaches up to 17–38% in older cases with chronic disorders and in intensive care unit (ICU) subjects. Diabetic patients, particularly those whose disease is not well controlled can be more susceptible to COVID-19. Although diabetes was present in 5.3%–42.3% of fatalities from COVID-19, the underlying pathophysiological mechanisms of action of novel coronavirus in diabetic patients are unknown. Based on the elevating of global prevalence, diabetes is the main medical problem associated with COVID-19. It is plausible that diabetes can forecast elevated severity of pneumonia. The mortality of lung infection among diabetes is remarkably higher compared with non-diabetic patients. Mechanisms responsible for severe pneumonia in the diabetic patients as well as treatment of diabetic patients infected with COVID-19 are largely speculative. Hence, this paper will summarize the recent findings related to the mechanisms of pneumonia and treatment strategies in diabetic patients.

show abstract

Letter from Iran: Experiences with COVID‐19

Cited by 4 publications

References 4 publications

Demand for mitigating the risk of COVID-19 infection in public transport: The role of social trust and fatalistic beliefs

Demand for mitigating the risk of COVID-19 infection in public transport: The role of social trust and fatalistic beliefs

Determination of Serum Calprotectin, Heparin-Binding Protein, and Some Inflammatory Factors in Patients with COVID-19

Diabetes and COVID-19: Mechanism of pneumonia, treatment strategy and vaccine

Contact Info

Product

Resources

About